MIB-1 labeling index in nonpilocytic astrocytoma of childhood

A study of 101 cases

Donald M. Ho, Tai-Tong Wong, Chih Yi Hsu, Ling Tan Ting, Hung Chiang

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

BACKGROUND. The prognosis of pediatric patients with nonpilocytic astrocytoma, and in particular those with anaplastic astrocytoma, is somewhat unpredictable. This study used MIB-1 monoclonal antibody, a proliferative marker that can be used in formalin fixed paraffin embedded tissues, to study nonpilocytic pediatric astrocytoma. METHODS. Astrocytoma, anaplastic astrocytoma, and glioblastoma specimens excised from a total of 101 pediatric patients during the period from January 1975 to September 1996 were retrieved from the authors' surgical pathology file. Histologic grading of the specimens was performed based on a modified Ringertz system. The proliferative potential of the tumors was estimated by using the MIB-1 labeling index (LI), which was evaluated with morphologic grades of tumors and survival of the patients. RESULTS. Of the 101 patients, 34 had astrocytoma, 33 had anaplastic astrocytoma, and 34 had glioblastoma. Their mean survival times were 165.2 ± 14.9 months (mean ± standard error; SE), 46.1 ± 9.9 months, and 21.8 ± 5.6 months, respectively. The mean MIB-1 LI of different tumor grades were as follows: astrocytoma, 3.9 ± 4.3 (mean ± standard deviation; range, 0.0-21.6); anaplastic astrocytoma, 24.3 ± 15.6 (range, 1.7-62.8); and glioblastoma, 35.9 ± 16.4 (range, 7.36-63.3). The mean survival of the entire group of patients with LIs ≤ 11 was 173.2 ± 12.2 months (mean ± SE), and the mean survival of those with LIs > 11 was 20.3 ± 4.1 months. The survival of anaplastic astrocytoma patients with LIs ≤ 11 was similar to that of astrocytoma patients, whereas the survival of anaplastic astrocytoma patients with LI > 11 was similar to that of patients with glioblastoma. CONCLUSIONS. The results of the current study show that histopathologic grading can predict the outcome for patients with astrocytomas and glioblastomas, whereas MIB-1 LI can separate better and worse prognostic groups in patients with anaplastic astrocytoma.

Original languageEnglish
Pages (from-to)2459-2466
Number of pages8
JournalCancer
Volume82
Issue number12
DOIs
Publication statusPublished - Jun 15 1998
Externally publishedYes

Fingerprint

Astrocytoma
Glioblastoma
Survival
Pediatrics
Neoplasms
Surgical Pathology
Paraffin
Formaldehyde
Survival Rate

Keywords

  • Astrocytoma
  • Childhood
  • Ki-67
  • MIB-1
  • Pediatric

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

MIB-1 labeling index in nonpilocytic astrocytoma of childhood : A study of 101 cases. / Ho, Donald M.; Wong, Tai-Tong; Hsu, Chih Yi; Ting, Ling Tan; Chiang, Hung.

In: Cancer, Vol. 82, No. 12, 15.06.1998, p. 2459-2466.

Research output: Contribution to journalArticle

Ho, Donald M. ; Wong, Tai-Tong ; Hsu, Chih Yi ; Ting, Ling Tan ; Chiang, Hung. / MIB-1 labeling index in nonpilocytic astrocytoma of childhood : A study of 101 cases. In: Cancer. 1998 ; Vol. 82, No. 12. pp. 2459-2466.
@article{e9c904f1fd1e476cbba00e82de78f7ac,
title = "MIB-1 labeling index in nonpilocytic astrocytoma of childhood: A study of 101 cases",
abstract = "BACKGROUND. The prognosis of pediatric patients with nonpilocytic astrocytoma, and in particular those with anaplastic astrocytoma, is somewhat unpredictable. This study used MIB-1 monoclonal antibody, a proliferative marker that can be used in formalin fixed paraffin embedded tissues, to study nonpilocytic pediatric astrocytoma. METHODS. Astrocytoma, anaplastic astrocytoma, and glioblastoma specimens excised from a total of 101 pediatric patients during the period from January 1975 to September 1996 were retrieved from the authors' surgical pathology file. Histologic grading of the specimens was performed based on a modified Ringertz system. The proliferative potential of the tumors was estimated by using the MIB-1 labeling index (LI), which was evaluated with morphologic grades of tumors and survival of the patients. RESULTS. Of the 101 patients, 34 had astrocytoma, 33 had anaplastic astrocytoma, and 34 had glioblastoma. Their mean survival times were 165.2 ± 14.9 months (mean ± standard error; SE), 46.1 ± 9.9 months, and 21.8 ± 5.6 months, respectively. The mean MIB-1 LI of different tumor grades were as follows: astrocytoma, 3.9 ± 4.3 (mean ± standard deviation; range, 0.0-21.6); anaplastic astrocytoma, 24.3 ± 15.6 (range, 1.7-62.8); and glioblastoma, 35.9 ± 16.4 (range, 7.36-63.3). The mean survival of the entire group of patients with LIs ≤ 11 was 173.2 ± 12.2 months (mean ± SE), and the mean survival of those with LIs > 11 was 20.3 ± 4.1 months. The survival of anaplastic astrocytoma patients with LIs ≤ 11 was similar to that of astrocytoma patients, whereas the survival of anaplastic astrocytoma patients with LI > 11 was similar to that of patients with glioblastoma. CONCLUSIONS. The results of the current study show that histopathologic grading can predict the outcome for patients with astrocytomas and glioblastomas, whereas MIB-1 LI can separate better and worse prognostic groups in patients with anaplastic astrocytoma.",
keywords = "Astrocytoma, Childhood, Ki-67, MIB-1, Pediatric",
author = "Ho, {Donald M.} and Tai-Tong Wong and Hsu, {Chih Yi} and Ting, {Ling Tan} and Hung Chiang",
year = "1998",
month = "6",
day = "15",
doi = "10.1002/(SICI)1097-0142(19980615)82:12<2459::AID-CNCR21>3.0.CO;2-N",
language = "English",
volume = "82",
pages = "2459--2466",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - MIB-1 labeling index in nonpilocytic astrocytoma of childhood

T2 - A study of 101 cases

AU - Ho, Donald M.

AU - Wong, Tai-Tong

AU - Hsu, Chih Yi

AU - Ting, Ling Tan

AU - Chiang, Hung

PY - 1998/6/15

Y1 - 1998/6/15

N2 - BACKGROUND. The prognosis of pediatric patients with nonpilocytic astrocytoma, and in particular those with anaplastic astrocytoma, is somewhat unpredictable. This study used MIB-1 monoclonal antibody, a proliferative marker that can be used in formalin fixed paraffin embedded tissues, to study nonpilocytic pediatric astrocytoma. METHODS. Astrocytoma, anaplastic astrocytoma, and glioblastoma specimens excised from a total of 101 pediatric patients during the period from January 1975 to September 1996 were retrieved from the authors' surgical pathology file. Histologic grading of the specimens was performed based on a modified Ringertz system. The proliferative potential of the tumors was estimated by using the MIB-1 labeling index (LI), which was evaluated with morphologic grades of tumors and survival of the patients. RESULTS. Of the 101 patients, 34 had astrocytoma, 33 had anaplastic astrocytoma, and 34 had glioblastoma. Their mean survival times were 165.2 ± 14.9 months (mean ± standard error; SE), 46.1 ± 9.9 months, and 21.8 ± 5.6 months, respectively. The mean MIB-1 LI of different tumor grades were as follows: astrocytoma, 3.9 ± 4.3 (mean ± standard deviation; range, 0.0-21.6); anaplastic astrocytoma, 24.3 ± 15.6 (range, 1.7-62.8); and glioblastoma, 35.9 ± 16.4 (range, 7.36-63.3). The mean survival of the entire group of patients with LIs ≤ 11 was 173.2 ± 12.2 months (mean ± SE), and the mean survival of those with LIs > 11 was 20.3 ± 4.1 months. The survival of anaplastic astrocytoma patients with LIs ≤ 11 was similar to that of astrocytoma patients, whereas the survival of anaplastic astrocytoma patients with LI > 11 was similar to that of patients with glioblastoma. CONCLUSIONS. The results of the current study show that histopathologic grading can predict the outcome for patients with astrocytomas and glioblastomas, whereas MIB-1 LI can separate better and worse prognostic groups in patients with anaplastic astrocytoma.

AB - BACKGROUND. The prognosis of pediatric patients with nonpilocytic astrocytoma, and in particular those with anaplastic astrocytoma, is somewhat unpredictable. This study used MIB-1 monoclonal antibody, a proliferative marker that can be used in formalin fixed paraffin embedded tissues, to study nonpilocytic pediatric astrocytoma. METHODS. Astrocytoma, anaplastic astrocytoma, and glioblastoma specimens excised from a total of 101 pediatric patients during the period from January 1975 to September 1996 were retrieved from the authors' surgical pathology file. Histologic grading of the specimens was performed based on a modified Ringertz system. The proliferative potential of the tumors was estimated by using the MIB-1 labeling index (LI), which was evaluated with morphologic grades of tumors and survival of the patients. RESULTS. Of the 101 patients, 34 had astrocytoma, 33 had anaplastic astrocytoma, and 34 had glioblastoma. Their mean survival times were 165.2 ± 14.9 months (mean ± standard error; SE), 46.1 ± 9.9 months, and 21.8 ± 5.6 months, respectively. The mean MIB-1 LI of different tumor grades were as follows: astrocytoma, 3.9 ± 4.3 (mean ± standard deviation; range, 0.0-21.6); anaplastic astrocytoma, 24.3 ± 15.6 (range, 1.7-62.8); and glioblastoma, 35.9 ± 16.4 (range, 7.36-63.3). The mean survival of the entire group of patients with LIs ≤ 11 was 173.2 ± 12.2 months (mean ± SE), and the mean survival of those with LIs > 11 was 20.3 ± 4.1 months. The survival of anaplastic astrocytoma patients with LIs ≤ 11 was similar to that of astrocytoma patients, whereas the survival of anaplastic astrocytoma patients with LI > 11 was similar to that of patients with glioblastoma. CONCLUSIONS. The results of the current study show that histopathologic grading can predict the outcome for patients with astrocytomas and glioblastomas, whereas MIB-1 LI can separate better and worse prognostic groups in patients with anaplastic astrocytoma.

KW - Astrocytoma

KW - Childhood

KW - Ki-67

KW - MIB-1

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=0032526213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032526213&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19980615)82:12<2459::AID-CNCR21>3.0.CO;2-N

DO - 10.1002/(SICI)1097-0142(19980615)82:12<2459::AID-CNCR21>3.0.CO;2-N

M3 - Article

VL - 82

SP - 2459

EP - 2466

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -